Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors by Alshaker, Heba et al.
Vol.:(0123456789) 
Breast Cancer Research and Treatment 
https://doi.org/10.1007/s10549-018-4900-1
PRECLINICAL STUDY
Field template-based design and biological evaluation of new 
sphingosine kinase 1 inhibitors
Heba Alshaker1,2 · Shyam Srivats3 · Danielle Monteil3 · Qi Wang1 · Caroline M. R. Low4 · Dmitri Pchejetski1 
Received: 18 December 2017 / Accepted: 19 July 2018 
© The Author(s) 2018
Abstract
Purpose Sphingosine kinase 1 (SK1) is a protooncogenic enzyme expressed in many human tumours and is associated with 
chemoresistance and poor prognosis. It is a potent therapy target and its inhibition chemosensitises solid tumours. Despite 
recent advances in SK1 inhibitors synthesis and validation, their clinical safety and chemosensitising options are not well 
described. In this study, we have designed, synthesised and tested a new specific SK1 inhibitor with a low toxicity profile.
Methods Field template molecular modelling was used for compound design. Lead compounds were tested in cell and 
mouse cancer models.
Results Field template analysis of three known SK1 inhibitors, SKI-178, 12aa and SK1-I, was performed and compound 
screening identified six potential new SK1 inhibitors. SK1 activity assays in both cell-free and in vitro settings showed that 
two compounds were effective SK1 inhibitors. Compound SK-F has potently decreased cancer cell viability in vitro and 
sensitised mouse breast tumours to docetaxel (DTX) in vivo, without significant whole-body toxicity.
Conclusion Through field template screening, we have identified a new SK1 inhibitor, SK-F, which demonstrated antitumour 
activity in vitro and in vivo without overt toxicity when combined with DTX.
Keywords Sphingosine kinase 1 · Molecular field template · Kinase inhibitor · Chemosensitisation · Docetaxel · Breast 
cancer
Introduction
Sphingosine kinase 1 (SK1) is a lipid enzyme with onco-
genic properties that converts pro-apoptotic lipid second 
messenger sphingosine into the anti-apoptotic lipid second 
messenger sphingosine-1-phosphate (S1P). SK1 is tightly 
regulated by growth factors, cytokines, receptor tyrosine 
kinases and pro-survival signalling pathways and plays a 
key role in several fundamental biological processes includ-
ing cell proliferation, regulation of apoptosis, cell migra-
tion, fibrosis, angiogenesis, nociception and inflammatory 
responses [1–7].
There is compelling evidence that SK1 activation con-
tributes to cancer progression and leads to oncogenic 
transformation [8], increased tumour growth [9] and 
impairment of apoptosis [10]. SK1 is a tumour-associated 
enzyme: high levels of SK1 expression have been shown 
in various human tumours such as blood, brain, breast, 
colon, lung, ovary, stomach, uterus, kidney, prostate, 
rectum and small intestine [11–16] where they enhance 
tumour neovascularisation [17] and metastatic potential 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1054 9-018-4900-1) contains 
supplementary material, which is available to authorized users.
 * Heba Alshaker 
 h.alshaker@uea.ac.uk
 * Dmitri Pchejetski 
 d.pshezhetskiy@uea.ac.uk
1 School of Medicine, University of East Anglia, 2.53 BCRE, 
Norwich Research Park, Norwich NR47UQ, UK
2 Department of Pharmacology and Biomedical Sciences, 
Faculty of Pharmacy and Medical Sciences, University 
of Petra, Amman, Jordan
3 Department of Surgery and Cancer, Imperial College 
London, London, UK
4 Drug Design Consultant, London, UK
 Breast Cancer Research and Treatment
1 3
by promoting motility and invasion of cancer cells [18]. 
High levels of SK1 expression or activity are associated 
with a poor prognosis in several human cancers, making it 
a key pathway in the search for targeted therapies [3]. SK1 
has an isozyme SK2, which is predominantly localised to 
cell organelles, and its role in cell proliferation/apoptosis 
is less well studied.
Multiple SK1 inhibitors have been synthesised and 
assayed in different biological systems. Sphingosine ana-
logue dimethylsphingosine (DMS), the first direct SK inhibi-
tor, was shown to elicit cancer cell growth inhibition and to 
provoke apoptosis [19]; however, it lacked specificity affect-
ing multiple lipid and protein kinases and had no selectivity 
between SK isoforms [20]. Another sphingosine analogue, 
FTY720, was shown to inhibit SK1 more selectively [21, 
22]. It is also a potent apoptosis inducer [23, 24] and has 
excellent chemo- and radiosensitising properties in prostate 
and breast cancer models [25–27]. L-threo-dihydrosphingo-
sine (safingol) also demonstrated SK-inhibiting properties 
[28].
Non-sphingosine analogues F-12509A and B-5354c were 
synthesised based on extracts from marine fungi Trichopezi-
zella barbata [29]. Similar to DMS, F-12509A appears to 
inhibit SK1 competitively which suggests that the sesquit-
erpene moiety of F-12509A may mimic the sphingosine-
conformation when binding to SK1’s active site, whereas 
B-5354c demonstrated non-competitive inhibition [29]. The 
administration of B-5354c triggers dose-dependent apopto-
sis in LNCaP and PC-3 prostate cancer cells and this may be 
reversed by upregulation of SK1 [30]. Another group of SK 
inhibitors (SKI-I-V) also possessing anticancer properties 
was reported by French et al [14, 31].
A selective SK1 inhibitor (SK1-I) ([(2-hydroxy-1-naph-
thyl)methylene]-3-(2-napythyl)-1H-pyrazole-5-carbohy-
drazide) efficiently induces apoptosis in leukaemia cells, 
but not in normal bone marrow-derived cells [32]. Xiang 
et al, have developed further SK1-specific inhibitors (6ag, 
9ab and 12aa) through a series of modifications of sphingo-
sine [33]. Amidine-based subtype-selective SK1 inhibitors 
induce reduction of endogenous S1P levels in human leu-
kaemia cells at nanomolar concentrations [34]. A research 
study investigating the structure–activity relationship of 
various analogues of SK1-I has demonstrated new inhibi-
tors with optimised selectivity and activity [35], noting that 
the naphthyl rings were unnecessary for SK1 inhibition. 
One such discovery was a small molecule SKI-178 which is 
active both in vitro and in vivo and could be useful in deter-
mining the exact functions of SK1 and SK2 isoforms in the 
development and progression of diseases [35]. Additionally, 
(S)-FTY720 vinylphosphonate [22] and sphingo-guanidines 
(LCL146 and LCL351) [36] induce SK1 inhibition in breast 
and prostate cancer cells and decrease the migration rate of 
human prostate DU145 cells.
Despite recent advances in SK1 inhibitors synthesis and 
validation, only most recent ones are isozyme specific (i.e. 
targeting SK1 and not SK2, which have distinct intracellu-
lar functions). Among these, only a few have been studied 
in animal systems and to our knowledge no general toxic-
ity or side effects studies (such as blood counts, liver and 
kidney function) have been performed. This is of critical 
importance, for future drug development as some of better 
described SK1 inhibitors (e.g. FTY720) have profound side 
effects that may render them unusable in cancer patients (e.g. 
lymphopenia, bradycardia and liver function tests derange-
ment) [37, 38]. Finally, we have previously shown SK inhib-
itor-mediated chemosensitisation to docetaxel (DTX) [6]; 
however, the clinical safety of such combination was not 
assessed.
In this study, we have used for the first time field template 
modelling to design new specific SK1 inhibitors. Lead com-
pounds were tested in cell and mouse cancer models and we 
found that compound SK-F has potently decreased cancer 
cell viability in vitro and sensitised mouse breast tumours to 
DTX in vivo, without significant whole-body toxicity.
Materials and methods
Reagents
Silica gel 60 high-performance TLC plates were purchased 
from VWR (West Chester, PA, USA), and [γ-32P]-ATP was 
purchased from Perkin-Elmer (Waltham, MA, USA). SK 
inhibitor SKI-II was purchased from Selleckchem (New-
market, UK). All other chemicals were from Sigma Aldrich 
(Poole, UK).
Field template molecular modelling
The detailed description of the field template method is 
provided in the supplementary data and was performed as 
previously described [39]. Briefly, electrostatic and van der 
Waals field points were calculated for sets of conformations 
whose energies lay within 5 kcal/mol of the global mini-
mum for the three SK1 inhibitors SKI-178, 12aa and SK1-I 
(Fig. 1a). This range was chosen on the basis that it covers 
all conformations likely to exist at physiological temperature 
(310K). These “molecular field patterns” were compared 
on a pairwise basis and FieldTemplater used to identify a 
field pharmacophore, one common field pattern for the three 
inhibitors (Fig. 1b). At the time of investigation, there was 
no protein structural information for these particular com-
pounds, and we consider that this ligand-based approach 
represents the most likely 3D-conformations adopted by the 
SKI-178, 12aa and SK1-I. Cresset Spark software was then 
used to find bioisosteric replacements for the portion of the 
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pharmacophore corresponding to the headgroup. The Spark 
database of 600,000 fragments was originally derived from 
molecules in ChEMBL and field point patterns calculated 
for each entity. Virtual libraries were constructed by attach-
ing field point fragments to the 4-n-octylphenyl tail of 12aa. 
The aim is to find bioisosteres with similar shape and elec-
tronic properties to the headgroup portion of the field point 
template pharmacophore. Each compound was overlaid with 
the field point pharmacophore and high scoring examples 
i.e. those with the highest field point similarity considered 
as potential candidates for synthesis. This process led to the 
design of the six structures of new SK1 inhibitors, SK-A to 
F. (Fig. 1c).
Nuclear magnetic resonance spectrometry
Nuclear magnetic resonance (NMR) spectra were recorded 
in 5-mm tubes calibrated to tetramethylsilane (TMS) at 
deuterated chloroform  (CDCl3), on a Bruker AM-400 
spectrometer.
Laboratory synthesis
The detailed description of the compound synthesis is pro-
vided in the supplementary data. Compounds SK-A, SK-B, 
SK-E, SK-F (Fig. 1c) were prepared as previously described 
[40] and compounds SK-C and SK-D were prepared by 
amide coupling as previously described [41].
Cell culture
Cell culture was performed as previously described [42, 43]. 
Human breast cancer cell line MDA-MB-231 and murine 
breast cancer cell line 4T1 were purchased from ATCC 
(Manassas, VA, USA), and maintained in DMEM with 10% 
fetal calf serum, 50 U/ml penicillin, 50 µg/ml streptomycin, 
Fig. 1  Molecular template design. a Structures of three SK1 inhibi-
tors, SKI-178, 12aa and SK1-I, used to prepare field point template 
pharmacophore. b Venn diagram illustrating process used to identify 
template. FieldTemplater generates a series of conformations that the 
ligands might adopt at physiological conditions. Field point patterns 
are calculated for each conformation and molecules compared on this 
basis. Four types of field point are illustrated: positive (red) and nega-
tive (blue) electrostatic points; van der Waals’ (yellow) and surface 
sticky points (orange). “Duos” are pairs of conformations with high 
field point similarity, indicated at points where only two circles over-
lap. A “trio” is a set of three conformations that show high field simi-
larity, indicated at the centre where all three circles overlap with one 
another. It is likely that such sets represent the bioactive conforma-
tions of the SK1 inhibitors, assuming that they all bind to the same 
protein site. The individual components of the template are shown 
together with the final assembly. c Target structures of potential SK1 
inhibitors were identified through “field screening” of available frag-
ment libraries using Spark software. These six compounds were syn-
thesised and tested
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and 2  mM glutamine (Sigma-Aldrich, St. Louis, MO). 
Cell lines were kept in culture for up to 30 passages. Cells 
were seeded to reach 70–80% confluence by the end of the 
treatment.
Cell treatment and preparation of cell lysates
Cells were plated, serum deprived, and treated as indicated 
in figure legends. After incubation, cells were washed with 
ice-cold phosphate-buffered saline (PBS) and harvested.
Cell viability
Cells were grown in 96-well plates, deprived from serum, 
and exposed to different treatments as indicated in fig-
ure legends. Cellular viability was measured using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; 5 mg/ml) colorimetric assay as already 
described [44].
RNA extraction, cDNA synthesis and qRT‑PCR
Isolation of total RNA from MDA-MB-231 cells was per-
formed using the RNeasy Mini kit (Qiagen, Valencia, CA, 
USA) as per manufacturer’s instructions. RNA quantity and 
purity were measured using a NanoDrop ND-1000 Spec-
trophotometer (Thermo Fisher Scientific, Loughborough, 
UK). Reverse transcription was performed using precision 
nanoScript™ reverse transcription kit (PrimerDesign Ltd, 
Southampton, UK). qRT-PCR was done as already described 
[26, 44]. Ct values were exported and analysed using qbase 
software (Biogazelle NV, Zwijnaarde, Belgium).
Sphingosine kinase assay
SK assay was performed using radiolabeling as previously 
described [45–47], in conditions favouring SK1 or SK2 
activity as required.
Animal study
Breast cancer allografts were established in 6–8-week-old 
BALB/c nude mice by injection of  106 4T1 cells into their 
mammary pad. Two weeks after implantation, mice were 
randomised into treatment groups (n = 6/group) and treated 
twice a week for 2 weeks with intraperitoneal injections of 
dimethyl sulfoxide (DMSO), 5 mg/kg DTX, 5 mg/kg SK-F, 
5 mg/kg DTX + 5 mg/kg SK-F. One day after the last treat-
ment, all mice were euthanized and blood was collected. 
Tumour long and short radii were measured using calipers 
and tumour volume (v) was calculated using the formula 
v = 4/3 πab2 (a – long radius, b – short radius). Mice and 
individual organs were weighed and primary tumours were 
then processed for analysis of SK1 activity as described 
above. Full blood count and liver function test analysis was 
done in the Hammersmith hospital biochemical lab.
Statistical analysis
Data are presented as the mean values of at least three 
independent experiments normalised to control ± standard 
error of the mean (SEM) calculated using GraphPad Prism. 
Statistical significance between two groups was conducted 
by unpaired Student’s t test. p value of < 0.05 is considered 
statistically significant.
Results
Design and synthesis of potential SK1 inhibitors
The Field Templater module of Cresset Forge was used 
to establish the common electrostatic and van der Waals’ 
features of the three known SK1 inhibitors SKI-178, 12aa 
and SK1-I (Fig. 1a) (please see detailed description of the 
method in the supplementary data). Electrostatic and van der 
Waals’ field points for each conformation of the three SK1 
inhibitors were calculated and features of these molecular 
field patterns common to all three SK1 inhibitors extracted 
in the form of a field template (Fig. 1b). The final template 
contains the field points associated with one conformation of 
each inhibitor and can be considered as a high content field 
point pharmacophore representing the features responsible 
for molecular recognition and binding.
New compounds were designed by searching fragment 
databases for the pattern associated with the polar head 
group using Cresset Spark. Six structures of new SK1 
inhibitors were identified and proposed to be SK1 inhibi-
tors on the basis of the similarity of their field point patterns 
scored against the pharmcophore template identified above. 
(Fig. 1c). The compounds were then synthesised and their 
mass spectra verified (Figures S1–S6).
Assessment of SK1 inhibitors in cell‑free and in vitro 
settings
The synthesised compounds were then screened for SK1 
inhibition. Compounds SK-A to SK-F and SKI-II (commer-
cial inhibitor of SK used as positive control with reported 
 IC50 0.5 µM [14]) at 1 µM were incubated in the presence 
of recombinant SK1 extract (in excess), 1 µM of ATP, and 
exogenous 1 µM sphingosine for 1 h followed by measure-
ment of SK1 activity. When compared with SKI-II, SK-F 
was the most potent inhibitor of SK1 activity in cell-free 
settings, followed by SK-E and then SK-D (Fig. 2a).
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Although the new SK1 inhibitors (SK-D, SK-E and 
SK-F) demonstrated potency toward inhibition of purified 
SK1 enzyme, it is important to determine their ability to 
inhibit endogenous SK1 in an intact cell model. Reportedly, 
among human tumour cell lines, the breast cancer cell line 
MDA-MB-231 expresses high levels of SK activity [14]. 
We treated MDA-MB-231 cells with 1 µM of compounds 
SK-A – SK-F and SKI-II as the positive control for 6 h and 
analysed SK1 activity in the cell lysates using SK1 activity 
assay. SK-C, SK-E and SK-F significantly decreased SK1 
activity when compared with vehicle-treated cells (Fig. 2b). 
Compound SK-F was the most potent inhibitor of SK1 activ-
ity in vitro achieving 48.2% inhibition. These results dem-
onstrate that compound SK-F is the most potent inhibitor 
of SK1 inhibiting not only purified but endogenous SK1 in 
intact cells (Fig. 2).
Interestingly, compound SK-C was ineffective in cell-free 
setting, but has significantly inhibited SK1 in vitro. We have 
therefore evaluated the effect of different concentrations of 
the new SK1 inhibitors on SK1 mRNA expression in vitro. 
Except for compound SK-C, the rest of the compounds dem-
onstrated no inhibition of SK1 mRNA expression at any con-
centration tested (Fig. 3). Overall, of all compounds tested, 
SK-F demonstrated a sustained SK1 inhibition both in cell-
free setting and in vitro without affecting its mRNA expres-
sion levels. Dose response analysis of SK1 activity showed 
that its  IC50 for purified enzyme was 0.92 µM (Figure S7).
To elucidate whether SK-F is a competitive inhibitor 
of SK1 and whether it binds to SK2, SK1 and SK2 activi-
ties were measured using recombinant SK1 and SK2 with 
increasing concentrations of sphingosine and the indicated 
concentrations of SK-F as shown on Lineweaver–Burk 
plots (Figure S8A, B). SK1 activity was determined in 
the presence of triton X-100 and SK2 activity was meas-
ured in the presence of high salt concentrations, conditions 
that favour SK1 and SK2, respectively. Our data show that 
SK-F is a competitive inhibitor of SK1. Km for SK1 was 
6.97 ± 1.20 µM, Vmax 98 ± 4 µM/min/mg protein and  Ki for 
SK-F 0.46 ± 0.1 µM. Lineweaver–Burk plot for SK2, showed 
no inhibition of SK2 by SK-F (Figure S8B). Some SK inhib-
itors such as SKI-II were previously shown to induce pro-
teasomal degradation of SK1 [48, 49]. Our data show that 
SK-F did not induce any change in SK1 protein (Figure S9).
It is expected that inhibition or silencing of SK1 will have 
antiproliferative effect on breast cancer cells [44]. We have 
assessed the effects of these inhibitors at varying concentra-
tions on triple-negative MDA-MB-231 breast cancer cells 
using MTT cell proliferation assay. Of all compounds tested, 
SK-C and SK-F showed the highest effect on MDA-MB-231 
cancer cell proliferation (Fig. 4). Based on these data, we 
have chosen compound SK-F to proceed with for further 
in vivo testing.
Fig. 2  Inhibition of sphin-
gosine kinase 1 in cell-free 
extract and in vitro. a 1 µM of 
compounds SK-A to SK-F and 
SKI-II (commercial inhibitor of 
SK used as a positive control) 
were incubated in the presence 
of recombinant SK1 extract 
(in excess), 1 µM of ATP, and 
1 µM exogenous sphingosine 
for 1 h. b MDA-MB-231 cells 
were incubated with 1 µM of 
compounds SK-A to SK-F and 
SKI-II for 6 h. SK1 activity was 
measured as described in mate-
rials and methods. Columns, 
means of three independent 
experiments normalised to vehi-
cle; bars, SEM. (ns, non-signifi-
cant; *p < 0.05; **p < 0.01)
Fig. 3  Effect of compounds SK-A to SK-F on SK1 mRNA levels. 
MDA-MB-231 cells were incubated with 1, 2, 5 and 10 µM of com-
pounds SK-A to SK-F for 24 h. SK1 mRNA expression was measured 
by qRT-PCR. Columns, means of three independent experiments nor-
malised to control; bars, SEM. (*p < 0.05; **p < 0.01)
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Compound SK‑F effect on SK1 and antitumour 
activity in vivo
To establish the applicability of SK1 inhibitors as anticancer 
therapeutic agents and for characterization of their whole-
body effects, we investigated the in vivo efficacy of com-
pound SK-F. For this purpose, we have used a mouse breast 
cancer model where triple-negative mouse breast cancer 
cells 4T1 were injected into the mammary pad of 6–8-week-
old female BALB/c nude mice. 4T1 cells have slightly lower 
levels of SK1 activity than MDA-MB-231 cells and showed 
a similar response to SK inhibition (Figure S10).
Tumour-bearing mice were divided into four groups 
(n = 6) and injected with: DMSO, 5 mg/kg DTX, 5 mg/kg 
SK-F, 5 mg/kg DTX + 5 mg/kg SK-F. Two weeks after the 
tumour cells inoculation, we began intraperitoneal injec-
tions of drug preparations and continued these twice a week 
for two weeks. Based on our previous studies [25, 26, 50], 
we have chosen relatively smaller doses of SK-F and DTX 
in order to investigate their combined effect and potential 
chemosensitisation of breast tumours to taxane therapies. 
In the control group, tumours grew progressively and rap-
idly (Fig. 5a). Treatment with SK-F alone has insignifi-
cantly decreased tumour volume relative to control group, 
with maximal results observed at the end of the study (371 
vs 468  mm3, respectively). Five mg/kg DTX has induced a 
significant reduction in tumour volume to 281  mm3. The big-
gest reduction in tumour volume to 159  mm3 was observed 
when DTX was combined with SK-F (Fig. 5a). Similar to 
in vitro findings, treatment with compound SK-F alone or in 
combination with DTX, significantly reduced tumour SK1 
activity (Fig. 5b). We have further investigated the effects 
of the used treatments on mouse whole-body toxicity. DTX 
has reduced body and liver weight, while SK-F had no sig-
nificant effect (Table 1). DTX has induced significant anae-
mia and leukopenia, while the effects of SK-F were very 
Fig. 4  Effect of compounds SK-A to SK-F on breast cancer cell via-
bility. MDA-MB-231 cells were incubated with 1, 2, 5 and 10  µM 
of compounds SK-A to SK-F for up to 120 h. Cell proliferation was 
measured using MTT assay. Columns, means of three independent 
experiments normalised to control; bars, SEM. (*p < 0.05; **p < 0.01; 
§p < 0.001). IC50 levels for SK-F for 72, 96 and 120 h were 7, 4.5 and 
3 µM, respectively
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moderate. In all cases, the effects of combined therapy were 
similar to DTX alone (Table 1). Liver function test was per-
formed as a surrogate marker for chemotherapy-induced 
liver damage (Fig. 6). DTX induced significant increases 
in alanine transaminases (ALT) and aspartate transaminase 
(AST) and a milder increase in alkaline phosphatase (ALP). 
In comparison to DTX, SK-F had a milder toxicity profile. 
The combination therapy had similar toxicity profile to DTX 
alone, while exerting higher antitumour efficacy (Fig. 5a).
Discussion
Sphingosine kinase 1 (SK1) is a protooncogenic enzyme 
expressed in many human tumours and associated with 
chemoresistance and poor prognosis [3]. It is a potent ther-
apy target and its inhibition chemosensitises solid tumours. 
Several SK1 inhibitors have been synthesised and tested 
in biological models with varied success (reviewed in: 
[51–53]). SK1 crystal structure was not known till recently 
and previous knowledge was largely based on site-directed 
mutagenesis and enzyme kinetics (reviewed in: [54]). The 
most potent SK1 inhibitor PF-543 has a  Ki of 3.6 nM and an 
 IC50 of 2 nM for SK1 [55]. In 2013, Wang et al have reported 
a crystal structure of SK1, which notably revealed that SK1 
3D structure bears no similarity to protein kinases or other 
lipid kinases and that Asp81 is a key catalytic residue that 
facilitates direct phosphoryl transfer [56]. A further dynam-
ics study and MM-PBSA binding free energy calculations 
study showed that residues Ile170, Phe188 and Thr192 in 
SK1 significantly contribute to a favourable binding energy 
and specificity for SK1 over SK2 [57]. This has led to a 
structure-based approach for design and synthesis of a series 
of SK1 inhibitors [58–60] .
Fig. 5  Effect of compound SK-F on breast tumour growth and SK1 
activity. Breast cancer allografts were established in BALB/c nude 
mice by injection of 4T1 cells into their mammary pad. Two weeks 
after implantation, mice were randomised into treatment groups 
(n = 6/group) and treated twice a week for 2 weeks with intraperito-
neal injections of: DMSO, 5  mg/kg DTX, 5  mg/kg SK-F, 5  mg/kg 
DTX + 5  mg/kg SK-F. a Tumour volume in the different treatment 
groups of 4T1 breast cancer implanted in mouse mammary fat pad. 
b SK1 activity in tumours was measured using radiolabelling. Points, 
columns, mean of n = 6 animals (in B normalised to control); bars, 
SEM. (*p < 0.05; **p < 0.01)
Table 1  Effect of treatment 
on whole-body toxicity, (% of 
control ± SEM)
a ns non-significant
*p < 0.05
**p < 0.01
§ p < 0.001 in comparison to control
Weight of
Body Lungs Liver Spleen Kidney WCC Hb
Control 100 ± 7 100 ± 4.8 100 ± 7.5 100 ± 15.4 100 ± 7.1 100 ± 6 100 ± 9
SK-F 91 ± 6ns 117.7 ± 5.6* 106.7 ± 5.5a 111.2 ± 13.4a 118.2 ± 3.6* 78 ± 7* 90 ± 8a
DTX 86 ± 7* 99.4 ± 4.a 85.3 ± 11.4a 91.3 ± 15.4a 97 ± 5.9a 54 ± 4§ 65 ± 7§
SK-F + DTX 84 ± 8* 114 ± 7.4* 98.1 ± 3.6a 112 ± 10.8a 110.8 ± 2.4* 56 ± 6§ 68 ± 5§
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In this study, we have used a ligand-based approach to 
design six new SK1 inhibitors [39]. If two diverse structures 
are known to act at the same protein active site, they are pre-
sumed to interact in similar ways with the protein. We have 
used molecular field points to summarise the electrostatic 
and van der Waals’ properties of molecules. These features 
can be used as the basis for comparing diverse molecules, 
particularly in cases where structural similarity is not obvi-
ous at first sight. These methods are the basis of the Cres-
set software packages Forge and Spark which have been 
successfully applied to scaffold-hopping between different 
chemotypes [61].
We have used the molecular field patterns of three known 
SK1 inhibitors: SKI-178, 12aa and SK1-I (Fig. 1a) to estab-
lish shared common pharmacophoric features (Fig. 1b). To 
find the optimal field overlay of two molecules, the field 
of every conformer of each selected molecule was com-
pared pair-wise until a close field match was found. The 
conformations from each pair having the most similar fields 
are assumed to represent the bioactive conformations. The 
conformations from two molecules often generate many 
duos with high field similarity. However, the chance that 
the “common” field is also generated by a third unrelated 
active molecule affords a useful refinement step. Therefore, 
by cross correlating all possible duos from three or more 
molecules acting at the same site, the conformers with the 
“common” field pattern are more reliably identified as the 
bioactive conformers.
This 3D information was used as input for Spark (Cres-
set, UK) in design of new compounds in which the polar 
headgroup of 12aa was replaced by fragments selected from 
the Spark database of field point isosteres. A virtual library 
of potential candidates was assembled and compared to the 
field point pharmacophore to prioritise examples for synthe-
sis. Six new structures were made (Fig. 1c) and their mass 
spectra verified (Figures S1–S6).
The synthesised compounds were then screened for cell-
free SK1 inhibition. Of six compounds tested only SK-E 
and SK-F showed statistically significant inhibition of SK1 
(Fig. 2a). This result represents a reasonable hit rate for this 
small set of compounds. Interestingly, three compounds, 
SK-C, SK-E and SK-F inhibited endogenous SK1 in an 
intact cell model (Fig. 2b), with compound SK-F achiev-
ing 48.2% inhibition, which was superior to SKI-II in our 
experiment. SK-F did not elicit any changes on SK1 mRNA 
expression at any concentration tested (Fig. 3).
Some SK inhibitors such as SKI-II were previously 
shown to induce proteasomal degradation of SK1 [48, 49]. 
Our data show that only SK-C induced a 75% decrease in 
SK1 protein (Figure S9). This decrease is, however, similar 
Fig. 6  Liver function tests of mice treated with SK-F and docetaxel 
(DTX). Breast cancer allografts were established in BALB/c nude 
mice by injection of 4T1 cells into their mammary pad. Two weeks 
after implantation, mice were randomised into treatment groups 
(n = 6/group) and treated twice a week for two weeks with intraperi-
toneal injections of: DMSO, 5 mg/kg DTX, 5 mg/kg SK-F, 5 mg/kg 
DTX + 5  mg/kg SK-F. a Alanine transaminases (ALT). b Bilirubin. 
c Aspartate transaminase (AST). d Albumin. e Alkaline phosphatase 
(ALP). f Total protein. Columns, mean of n = 6 animals normalised to 
control; bars, SEM. (*p < 0.05; **p < 0.01)
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to the reduction in SK1 mRNA induced by this inhibitor and 
therefore does not suggest any protein-specific action. Con-
versely, SKI-II had a minimal effect on SK1 mRNA (Fig. 3), 
but induced significant decrease in SK1 protein (Figure S9) 
as previously reported [48, 49]. SKI-178, 12aa and SK1-I 
have all been shown to be SK1 specific and not to inhibit 
SK2. SKI-178 was shown to inhibit SK1 at the sphingosine 
binding site, but not at the ATP binding site [62]. Similarly, 
SK1-I was shown not to bind to the ATP pocket and to be 
competitive with the lipid substrate [47]. 12aa has no data 
regarding its binding site [33]. Lineweaver–Burk plots dem-
onstrate that SK-F is a selective SK1 inhibitor (Figure S8B) 
and a competitive inhibitor of SK1 (Figure S8A).
It is expected that inhibition or silencing of SK1 will 
have antiproliferative effect in breast cancer cells [26, 44]. 
In triple-negative MDA-MB-231 breast cancer cells, SK-F 
induced significant loss of proliferation (Fig. 4). This is par-
ticularly interesting since some recent SK1 inhibitors with 
sub-micromolar potency (e.g. PF-543) did not demonstrate 
cytotoxic effects in various cancer cell lines [55, 63, 64]. 
There is, however, significant evidence showing anticancer 
cytotoxic effects of SK1 siRNAs [44, 50, 65–67], confirm-
ing SK1 as a molecular target for anticancer therapy. SK-C 
also demonstrated some activity, but as this compound did 
not show any activity against the isolated enzyme we can 
conclude that this is either an off-target effect or that this 
compound is cytotoxic.
Despite the recent determination of the structure of SK1 
and a surge in SK1 inhibitor modelling studies, few SK1 
inhibitors have been tested in animal cancer models with sat-
isfactory results (reviewed in [68]). To further establish the 
applicability of SK-F as anticancer therapeutic agent and to 
characterise its whole-body effects we have investigated its 
action in the mouse triple-negative breast cancer model. We 
have combined it with DTX, an antineoplastic taxane that is 
widely used for the treatment and management of patients 
with breast cancers. However, drug-related cumulative toxic-
ity, unresponsiveness to DTX therapy, and the development 
of resistance limit its clinical benefits [69]. In our previous 
studies, we have shown that 3–5 mg/kg doses of SK1 inhibi-
tor FTY720 sensitise breast tumours to subtherapeutic doses 
of DTX [25, 26]. Here we have investigated whether SK-F 
will have a similar effect. Five mg/kg SK-F alone did not sig-
nificantly alter the tumour volume relative to control group. 
It has, however, significantly sensitised tumours to 5 mg/kg 
DTX (tumour volume of 159  mm3 in SK-F + DTX group 
vs 281  mm3 in DTX alone) (Fig. 5a). Similar to in vitro 
findings, treatment with compound SK-F alone or in com-
bination with DTX significantly reduced tumour SK1 activ-
ity (Fig. 5b), while DTX alone had no effect. These data 
are supported by in vitro experiment where 4T1 cells show 
significant inhibition of SK1 activity in response to SK-F 
(Figure S10).
For every proposed targeted therapy, it is crucial to iden-
tify potential side effects. Our toxicology study showed that 
contrary to DTX, SK-F did not induce significant mouse 
body weight loss, or organ weight loss (Table 1). SK-F had 
a milder liver function test profile than DTX and their com-
bination did not have any additive toxicity (Fig. 6). SK-F 
induced a very mild leukopenia and no anaemia (Table 1). 
This is a very important finding since the only clinically 
used SK1 inhibitor FTY720 induces a marked lymphopenia 
and therefore is not suitable for cancer patients as a free 
drug. However, in a view of significant DTX toxicity, it may 
be prudent to consider the use of these drugs in nanoformu-
lations [25, 26].
These findings are particularly important considering a 
recent report of a safe use of a putative inhibitor of SK safin-
gol in a phase I clinical trial, in combination with cisplatin in 
43 cancer patients. Safingol administration did not cause any 
significant side effects and one patient with adrenal cortical 
cancer was reported to have a significant regression of liver 
and lung metastases and another had prolonged stable dis-
ease [70]. Overall, through field template screening, we have 
identified a new SK1 inhibitor SK-F, which demonstrates 
antitumour activity in vitro and in vivo without overt toxicity 
when combined with DTX.
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